Annual Report

2018-2019

PATRON

THE HONOURABLE
KIM BEAZLEY, AC
GOVERNOR OF
WESTERN AUSTRALIA

The Lions Cancer Institute provides, voluntarily, a much needed support to available health services throughout Western Australia. In recent years this support has extended to South Australia, Victoria and New Zealand, and with the support of Lions, has now become a National Project.

In addition to providing funding to PhD students in cancer studies from universities in Western Australia, the Institute has, since 1990, conducted free skin cancer screenings as a service to the public. This is done with the generous voluntary assistance of a number of plastic surgeons, dermatologists, doctors, nurses and Lions Members, all of whom provide their services free to the Institute.

The majority of these screenings are conducted in country areas where such services are few, or non-existent. This is a service that has proven to save lives in our communities and will continue to do so with our support.

PATRON

PROF. GEORGE YEOH,
BSc, PhD.
PRESIDENT WA
CANCER COUNCIL

It is an honour to be appointed Patron of the Lions Cancer Institute for many reasons. It is an organisation that serves the community; and especially its rural and remote members who have poorer outcomes as a result of cancer. It is distinguished by having a large body of dedicated and highly qualified volunteers who make a difference to cancer patients, and particularly those with skin cancer. The war against this dreaded disease must be waged on many fronts. These include acquisition of knowledge of the enemy to exploit its weakness through research; adopting lifestyle practices that reduce its incidence through education and advocacy and improving diagnosis by increased surveillance and precision in detection. The Lions Cancer Institute is working on all these fronts by providing resources to support activities that underpin these strategies.

Fortunately, Australians derive enormous benefit from an excellent health system; however, as our population ages, the burden of cancer will increase proportionately. Thus numerically, the “enemy” will be more and more substantial. Today, more than a million Australians are cancer survivors. This is a testament to the effectiveness of the anti-cancer organisations that take up the call to fight this disease. The Lions Cancer Institute is a proud member of this group that will collectively confront escalating challenges into the future. I salute the volunteers of this organisation for all their contributions past and outcomes achieved. I thank you for the opportunity to join you for the journey we will take together in the future.

CONTENTS

2018/2019 Board of Directors	5
Chairman	6-7
Club Donations	37
Life Fellows of LCI	38
Media Release	12-13
Medical & Scientific Advisory Chairman	10
National Category “B” Skin Screening Project	20-21
Organisational Chart	9
PhD Students	16-19
PR & Business Development	8
Screening Events Manager	14
Screening Map 2018-2019	15
Sun Sense Advert / Kwik Kopy Canning Vale	39
Treasurer	22

Lions Cancer Institute Inc.

ABN: 26 521 960 054

The Lions Cancer Institute Inc. is a “Not For Profit” medical research institution. The Institute holds an Endorsement from the Australian Tax Office as an income tax exempt charitable entity (ITEC) and is a deductable gift recipient (DGR).

The Institute holds a licence issued under the provisions of the Charitable Collections Act.

Auditor/Accountant is Dharam Ghandis, Auditax Accountants, North Perth WA.

Institute website: www.lionscancerinstitute.org.au

BOARD OF DIRECTORS

ELECTED MEMBERS

Lion Phil Chinnery	Chairman
PDG Pamela Baird	Vice Chairman
PDG Garry Irvine	Director PR / Business Development
Lion David Baird	Director Assistant Treasurer
Lion John Osborne	Director Screening Events Manager
Lion Mary Austin	Director
Lion Stephen Berry	Director
Lion Michael Wainwright	Director
Lion June Walker	Director

APPOINTED MEMBERS

William (Bill) Crosthwaite	Secretary
PDG Neil F. Saunders	Treasurer
Dr Rob Fitzpatrick FRCS, FRACS	Chair Medical & Scientific Advisory Committee

EX OFFICIO MEMBERS

DG Luen Chicote	District Governor 201W1
DG Beverley Hawkins	District Governor 201 W2
1st VDG Daniel Stevens	1st VDG 201W1
1st VDG Frank Camarri	1st VDG 201W2
Lion Leonie Getty JP	District Chairman 201W1
PDG Darrel Mainard	District Chairman 201W2

CHAIRMAN'S REPORT

LION PHIL CHINNERY

It is my pleasure to provide this report on the status and progress of the Lions Cancer Institute Inc. over the preceding 12 months.

SKIN CANCER SCREENING

The Lions Cancer Institute Inc. commenced its screening program in 1990 and has conducted skin cancer screenings continuously, operating as the Lions Cancer Institute Inc. It has screened in the order of 85,000 people in that time, all over Western Australia.

It is now part of the National Category 'B' Skin Cancer Screening Project that commenced in effect from July 1, 2018 for a term of three years to June 30, 2021 following a successful submission jointly with C1 & C2 (South Australia) to the Lions Multiple Districts Convention held in Townsville.

South Australia commenced operation in 2012 and operates as a sub-committee under the Lions Medical Research Foundation of South Australia. The project in SA was set up with the assistance and guidance of the WA operation. It has screened around 13,000 people to date, including in the NT.

The Lions V Districts Cancer Foundation Inc commenced being established in September 2018 and is expected to become operational in early 2020, once again with the guidance of the WA project.

The West Australian project is going from strength to strength with an increasing number of requests by both Lions Clubs, other community organisations and businesses seeking skin screening services. The support of the Western Australian Chapter of Dermatology and several GP's combined with our fully trained Dermoscopists and Nurses has once again allowed an increase in the number of screenings this year.

The Institute now has a formal agreement in place with HealthCert Queensland, which is University based to provide a Certificated course in Assessment and Diagnosis of skin cancer lesions. Two of our volunteers completed the course this year and currently a further four are studying to complete their training by late December 2019. By having these additional trained Screeners, we can go out on screening events which relieves those that have carried the load over many years.

One of our Senior Screeners, PDG Colin Beauchamp AM JP has been travelling to South Australia and Victoria to support and assist with training and set up of their Projects, as well as helping with screening at times. As the Project is taken up by other Lions Districts, we will offer the same assistance and guidance where possible.

You will read more about our work on screening in Screening Event Manager Lion John Osborne's report elsewhere in this document.

RESEARCH

The Institute this year will fund through the Karen & Joshua Chinnery Scholarship two PhD students. Lelinh Duong and Jade Newton both attend Curtin University and were assessed by Cancer Council WA and recommended to the Institute. Jade is funded by the scholarship for 3 years, Lelinh for 1 year. Medical Director Rob Fitzpatrick will maintain contact with them during their time under the scholarships.

The Lions Cancer Institute and Curtin University have announced a new PhD scholarship that aims to improve the outcomes of people living with liver cancer around the world.

The Lions-Lotus PhD Scholarship has been fully funded by The Lions Cancer Institute and will be based in the Curtin Health Innovation Research Institute (CHIRI) at Curtin University.

A Letter of Intent was signed by representatives of both parties at a ceremony on August 1, 2019.

It is hoped a suitable student will be selected during 2020, to commence a three-and-a-half-year course of study in prevention and treatment of liver cancer. This association with Curtin means Lions Clubs in WA will now be able to visit the CHIRI by appointment and see firsthand the work being undertaken by researchers.

PATRONS

I am pleased to advise we have now a second Patron, The Honourable Kim Beazley AC, Governor of Western Australia. The Governor joins Patron Professor George Yeoh a distinguished researcher having spent most of his professional life in the study of cancer, most particularly seeking a cure for liver cancer.

INSTITUTE MANAGEMENT

Throughout this annual report you will also read reports from our Treasurer, PDG Neil Saunders, PR & Business Development Director PDG Garry Irvine, Skin Cancer Screening Events Manager Lion John Osborne, Medical Director Rob Fitzpatrick FRCS, FRACS Plastic Surgeon (Retired) and our current PhD students.

The Institute is well served by a Board consisting of Lions Club members and willing Volunteers, both in the administration of the Institute and on our skin cancer screening events throughout the State of Western Australia. To you all, I offer my sincere thanks for your dedicated involvement.

■ **Lion Phil Chinnery—Chairman**

▲ PHD STUDENT JADE NEWTON AND PHIL CHINNERY

▲ PHD STUDENT LELINH DUONG AND PHIL CHINNERY

PR & BUSINESS DEVELOPMENT

PDG GARRY IRVINE

In compiling this Report there has been a great deal of activity as far as our Business Development and Marketing areas are concerned and I am most appreciative of the support from members of the Board for their interest and contributions.

ADVERTISING

Currently we have a small budget for Advertising so as funds grow so will the budget. We have over the year trialled a subscription to a Seniors publication but after a review we found that to have been of little value to the Institute. We have been involved in a Cancer promotion lift out with the West Australian and received good feedback from that, in addition we have elected to have six articles over 12 months in the Farmers Weekly and are confident that the exposure in that will give us a voice within the country and regional communities. We have registered with CBH and have a Growers number which will allow grain farmers to allocate a portion of their crop profits to the Institute via CBH.

Advertising to obtain donations has been aided with every patient now receiving a copy of our LCI brochure which includes the opportunity of a donation and/or a bequest once they have been screened. We also have introduced a credit card facility as we move closer to becoming a cashless society.

One of the most effective forms of advertising is the telemarketing service which not only produces valuable funding to enable us to survive doing what we do but it puts our name and the service we provide to businesses throughout the State every day a phone call is made.

Thanks to all the Lions Clubs that donate to the work carried out by our volunteers and to the costs around keeping our two mobile screening units on the road. A reminder to those Clubs who may have overlooked the need for us to have their help, again please consider us when next you have funds available.

BUSINESS DEVELOPMENT

Thanks to Chairman Phil and the Executive we have begun a process to allocate areas of responsibilities to Board members which now ensures full participation and this has resulted in a Screening Roster which has a six month lead time so that planning of dates, locations, screeners and drivers is available on the website.

WEBSITE

Our new website is operating and will continue to have updates around all activities of the Institute.

BUSINESS PLAN

A Business Plan is in the process and our strategies by which we put that into action will evolve with the assistance of our contact in Liz Clarson who is donating her time and experience to bring this about.

NZ LIAISON

Some three years has passed since my first attempt to put the proposal of a skin screening programme to the NZ Lions, however this year we were successful in receiving an invitation to address the Lions National Convention in Blenheim and my thanks to PDG Colin Beauchamp AM., JP. for joining me in that opportunity. We met with most of the attendees and received indication of active support, all the incoming District Governors have received packaged information on the project. We are very hopeful that we will receive contact from the many ‘leaders’ we met with who indicated a determination to work with us to establish a free skin cancer screening service throughout NZ.

A follow up article with a photo of us at our Booth at Convention will be included in the July issue of the NZ Lion magazine.

■ **Garry K Irvine PDG 78/9**

ORGANISATIONAL CHART



MEDICAL & SCIENTIFIC ADVISORY CHAIRMAN'S REPORT

ROBERT FITZPATRICK
FRCS. FRACS.

This year marks a new system of reporting which is difficult to compare with previous results. Our reporting has changed from a calendar year to a 'financial' year and therefore the second 6 months of last year has also been counted in this year's figures. Despite this, the figures for the two periods are extremely similar as far as referrals are concerned with a constant rate of 20-22 % overall.

PARADOX

In 2018 3746 people were screened. Our numbers this year to date are probably a little down on last year. It is interesting that the referral rate for the corporates is about 5% lower than the general population and W1 is 6% lower than W2. This is a little surprising as the areas covered are all rural, coastal and urban areas with the majority of W2 being South of W1. It would be interesting to see whether people in hotter areas protect themselves more efficiently or is it the radiation levels are higher further South? Another interesting survey would be to ascertain the percentage of referred patients who attended their GP and the result of that consultation. Unfortunately, the LCI cannot do this as it could be seen to involve Duty of Care legalities. Possibly it could be done under the auspices of a university public health survey by a student. Now we have no way of knowing the efficacy of our referral system!

VOLUNTEERING AND TRAINING

Our screening roster is limited by the availability of screeners and those who are willing to spend some weekdays away. Most of the screeners are retired or can only work at weekends. During the year we had 5 people complete a basic course in Dermoscopy, 3 of whom have now enrolled in a University based course. Unfortunately, the course is not the end of training as to be confident in a decision to refer a patient requires the screener to have examined many patients under supervision. This year we have been lucky to have the services of Dr Alan and Mrs Diane Wright who have helped enormously with the screenings in country areas. Without them a few of our sites would have been cancelled. There have only been a handful of GPs' and working specialists that have volunteered during the year which I find disappointing. It is important to advertise the fact that we need screeners. Each person who reads this must visit their GP or know a nurse; tell them of the work we do and suggest that they may find it satisfying to volunteer as a screener. Even if they are not familiar with a dermascope they would gain CPD points for doing a course if they had not done one. The courses are online and can be conveniently taken from home in one's own time and would be free

EDUCATION

We still have the duty to educate people about **prevention, detection and early treatment.**

The reports of our current two and previous scholarship holders are in this annual report.

Finally, the Lions Cancer institute has now established another scholarship with Curtin University for a research in Liver cancer. This was as a result of a suggestion from one of our patrons, Professor George Yeoh. The first recipient should start next year.

■ **Robert Fitzpatrick FRCS, FRACS—Plastic Surgeon (Retired)**

MEDICAL & SCIENTIFIC ADVISORY CHAIRMAN'S REPORT

"BECOME INVOLVED" VOLUNTEER RECRUITMENT CAMPAIGN ▶

New Curtin Scholarship to help improve outlook for liver cancer patients

Curtin University and the Lions Cancer Institute Inc. have announced a new PhD scholarship that aims to improve the outcomes of people living with liver cancer around the world.

The Lions-Lotus PhD Scholarship has been fully funded by the Lions Cancer Institute and will be based in the Curtin Health Innovation Research Institute (CHIRI) at Curtin University.

The scholarship recipient, who will be supervised by Associate Professor Nina Tirnitz-Parker from CHIRI and Curtin's School of Pharmacy and Biomedical Sciences, will conduct cutting-edge research dedicated to the prevention and treatment of liver cancer.

CHIRI Director Professor John Mamo said the new scholarship would assist in tackling a major global disease affecting thousands of Australians every day.

"The new scholarship will attract high-quality PhD candidates, who will undertake research focusing on addressing important research questions about chronic liver disease and liver cancer," Professor Mamo said.

▲ LION PHIL CHINNERY & ASSOCIATE PROFESSOR NINA TIRNITZ-PARKER

"I would like to thank the Lions Cancer Institute for their funding commitment to this highly important scholarship and look forward to welcoming the successful recipient to Curtin University."

Associate Professor Nina Tirnitz-Parker, an internationally recognised expert in chronic liver disease and cancer, said chronic liver disease was one of the most rapidly growing causes of death worldwide and continued to present a major global challenge.

"Current treatments for liver cancer are limited and at present only prolong the life expectancy of patients by two to three months. The new scholarship will help to tackle this growing problem by researching how to better identify and treat the disease, which in turn may improve outcomes for people living with liver cancer," Associate Professor Tirnitz-Parker said.

The Chairman of the Lions Cancer Institute Mr Phil Chinnery said he looked forward to visiting Curtin University and seeing first-hand the work being undertaken by researchers.

"On behalf of our Directors and our WA Lions Clubs, we are both excited and delighted to have formed this partnership with Curtin University and their brilliant research team in the fight against cancer and more specifically liver disease," Mr Chinnery said.

The new agreement, signed recently, will fund a full PhD scholarship for up to 3.5 years and will be available to domestic PhD students in Australia. The successful recipient will commence at Curtin in late 2020 or beginning of 2021.

> I would like to thank the lions cancer institute for their funding commitment to this highly important scholarship and look forward to welcoming the successful recipient to Curtin University.
>
> - Professor Mamo

▼ CHIRI AND LCI TEAM MEMBERS

SCREENING EVENTS MANAGER REPORT

JOHN OSBORNE

Almost 50% of the people who attended our screenings during the past 12 months had never been screened or had been screened more than 12 months ago. This again highlights the importance of providing our screening service to the rural and remote areas of Western Australia. 20% of the people screened were referred to their General practitioner for further investigation of their suspect lesions.

Our screening program for the year started with screening in the Kimberley's and the Pilbara before returning south to screen in the Great Southern, South West and Northern Wheatbelt regions. We provided 43 days of screening in 38 different locations throughout the state.

The maintenance of our screening vehicles contributed to significantly to our operating costs. The total over the three units was $36 792.

Coach maintenance included the repair of the suspension Towers. Replacement of the levelling system and repair of hydraulic cylinder. Replacement of worn engine mounts and bushings in the rear suspension.

The Hino truck had repairs to the clutch.

The screening van had the electrical system upgraded following a minor electrical fire.

I would like to acknowledge the service of our volunteer screeners, trainees, drivers and administrators who give their time freely to ensure that we can take our screening program to the community of western Australia.

■ **John Osborne—Screening Events Manager**

NB: all figures below are for the 01/07/2018 - 30/06/2019 period.

2987 TOTAL SCREENED

Number of Referrals	605
% Referred	20%
Life Threatening Lesions	494
Screened less than 6 months	117
Screened 6 - 12 months	396
Screened over 12 months	1395

1079 NEVER SCREENED

Number of Locations	38
Days Screening	43
Hours Screening	1358

11713 KM TRAVELLED

Expenses - Screning Events

Accomodation	$19,492.64
Travel - Air Fares, Parking, Mileage	$17,354.63
Sustenance	$11,163.31
Fuel Coach	$5,089.19
Fuel Hino	$2,391.27
Fuel Gensets	$497.45

Expenses - Maintenance

Generator Sets	$413.35
Hino	$2,242.55
Coach	$31,084.07
Van	$3,053.07

$7978 SPENT IN FUEL

2018-2019 screenings

= Total Screened

= Referred

July 2018 Screenings in Green

July 2019 Screenings in Navy



Time since last screened 2018-2019

Screening expenses by region 2018-2019

PHD STUDENT'S FIRST REPORT

JADE NEWTON

PROJECT TITLE

Are Western Australian advanced cancer patients' psychosocial support needs being met? A mixed methods investigation of the provision and utilisation of psychosocial support for advanced cancer patients with non-haematological malignancies.

SUMMARY

Some people are diagnosed with cancer that has spread to other parts of their body and they are not able to be cured. This is 'advanced cancer'. We don't know a lot about how people with advanced cancer manage the emotional and social (or, 'psychosocial') impact of their diagnosis, and how available support affects their experience.

This project will explore what psychosocial support people with advanced cancer use, how it impacts them, and the costs and benefits of using psychosocial supportive care. This will be achieved by looking at what research has been done in this area, interviewing people with advanced cancer to learn about their experiences, and undertaking a cohort study, where we will survey patients over six months to look at their needs, distress, and support services used over time.

Understanding the needs and service use of people with advanced cancer will help to make sure we are providing the best support to lessen the distress and suffering they may experience.

PROJECT UPDATE

At the beginning of 2019, I was fortunately awarded a Lion's Cancer Institute PhD Top Up Scholarship, which has helped me to swap from studying part time whilst working three days a week to studying full time and focussing on my research.

During March to July 2019, I undertook a Health Economics unit at Curtin University, and in April 2019, I successfully applied for and received an expenses-paid trip to Melbourne to attend a workshop on using existing datasets in Australia. The skills and knowledge learned are directly applicable to the planned cohort study.

With the assistance of the Consumer and Community Health Research Network, in April 2019 we recruited two consumers to be involved with the project through providing feedback on study design and participant documents.

In May 2019, this project received faculty approval from Curtin University to start undertaking the research.

Currently, several applications are in progress to gain approval to start interviewing people about their experiences. People receiving care for an advanced cancer diagnosis will be recruited from Sir Charles Gairdner Hospital, and Saint John of God Hospital in Midland. I am also developing the protocol for a literature review which will investigate what is currently known about how organisations provide supportive care services.

I would like to thank the Lion's Cancer Institute for their generosity and kindness, and greatly appreciate their support to undertake this work.

■ **Jade Newton—PhD student from The Curtin University**

PHD STUDENT'S FIRST REPORT

LELINH DUONG

INVESTIGATING HOW KEY IMMUNE CELLS, KNOWN AS MACROPHAGES, CONTRIBUTE TO TUMOUR GROWTH IN THE ELDERLY AND IMPAIR RESPONSE TO THERAPY

Background

The Australian population is ageing, and cancer rates increase with old age, including mesothelioma and lung cancer. Prognosis for these types of cancers remain poor and anti-cancer treatment options are limited and may not be effective. This may be due to the impairment of the immune system with ageing. Macrophages are an immune cell type which can help fight cancer cells. However, macrophages can be easily persuaded to help tumours grow. Many tumours can be made of up to 50 percent macrophages and the number is associated with poor clinical outcome. Currently, few studies have looked at the effect of ageing on macrophages and no studies have looked at it in mesothelioma and lung cancer. The purpose of my project is to investigate if there are changes during ageing that cause macrophages to be more tumour promoting.

RESEARCH AIMS

1. To determine if macrophages become more tumour-promoting in older age
2. To assess the mechanisms by which macrophages in the tumour from the elderly are resistant to anti-cancer therapy

SUMMARY OF FINDINGS

Aim 1

We have found that in our mouse model of mesothelioma and lung cancer the tumours grow faster in elderly compared to young. Notably, there were significantly more macrophages in the tumours of the elderly. As tumours developed, the tumour-promoting "bad" type of macrophages increased in number and this happens quicker in the elderly compared to young.

I investigated how macrophages used sugar for energy, as this is important for their function. We found that the "bad" macrophages were consuming more sugar. Concurrently, they produced higher amounts of the molecules known to promote tumour growth, contribute to further inflammation in the tumour and instruct other macrophages to infiltrate the tumour.

Next, I looked at a communication pathway inside the cells, called mammalian target for rapamycin; which is involved in regulating energy metabolism and closely linked to how macrophages function. I found there was a breakdown in this communication pathway in macrophages in the tumour as they converted to the "bad" type. Specifically, the "brake" which prevents this pathway being overused had been lifted. This likely facilitates the excessive uptake of sugar; which may provide macrophages with the energy required to produce more molecules that can promote tumour growth. Importantly, this "brake" appears to be lifted earlier in the elderly compared to young. This could explain why we see more of the "bad" macrophages earlier during tumour progression in the elderly.

Studies are ongoing to further characterise how macrophages become more tumour-promoting in the elderly. The findings from Aim 1 will identify components that can be blocked with drugs to reverse or stop macrophages from converting to the "bad" type.

Aim 2

Our group had previously shown that macrophages in the elderly can sabotage the anti-cancer effects of immunotherapy. Aim 2 will examine how macrophages from the elderly are hindering immunotherapy as per Aim 1. I will then treat mice with immunotherapy with/without the drug as per Aim 1. These findings will identify ways we can improve immunotherapy in the elderly.

Significance

This project will help advance our understanding of how macrophages promote the development of tumours and impede on therapy effectiveness; and how it changes with age. This will help guide the design of effective anti-cancer therapies for the elderly. Additionally, these findings may be relevant to other cancers, such as prostate and colorectal. Ultimately, I hope to identify ways to improve outcomes for all cancer patients.

■ **Lelinh Duong—PhD student from The Curtin University**

PHD STUDENT'S FOURTH REPORT

TRACEY SEYMOUR

My PhD research focuses on finding more effective therapies for the most lethal human brain tumour, glioblastoma. Current treatment for glioblastoma includes safe maximal surgical resection, followed by radiotherapy and chemotherapy such as temozolomide. However, these treatments are not curative and patients only rate of survival is between 12 to 15 months from diagnosis. A reason for these treatments not being curative is that glioblastoma cells having the ability to resist the damaging effects of radiotherapy and temozolomide.

My PhD research involves pre-clinical studies that is currently testing a therapy, in hope that it will improve patient outcomes and extend survival.

CURRENT RESEARCH AIMS:

1. Determine whether new treatments will interact together with radiotherapy and/or chemotherapies such as temozolomide and gemcitabine.
2. Explore the mechanism in which these new therapies help to improve tumour cell death.
3. Examine whether combining new therapies to radiation therapy or chemotherapies such as temozolomide and gemcitabine will provide a survival benefit.

AIM 1

Determine whether new treatments will interact together with radiation therapy and/or chemotherapies such as temozolomide and gemcitabine.

Background

The standard of care for glioblastoma includes safe maximal resection, followed by radiotherapy and chemotherapy with temozolomide. This treatment protocol is not curative and tumour growth is still very rapid with a mean survival rate of only 12 to 15 months. Furthermore, glioblastoma has shown resistance to radiotherapy and temozolomide through the ability of repairing the DNA damage induced by these therapies. This particular study aims to prevent the DNA damage repair pathway with new therapies to enhance glioblastoma cell death.

Findings

Using several human glioblastoma cell lines, we have tested three new drug therapies. These therapies were tested alone or in combination with radiotherapy, or chemotherapies temozolomide and gemcitabine. The most promising therapy was LY2606368, an inhibitor of a protein called cell cycle checkpoint kinase 1/2. We have shown that LY2606368 causes a reduction in glioblastoma cell growth. More importantly, when combined with radiotherapy or temozolomide or gemcitabine, LY2606368 was compatible, where combination therapy produced enhanced glioblastoma cell death.

Significance

This study shows that combining LY2606368 to the current treatment of glioblastoma can enhance glioblastoma cell death.

AIM 2

Explore the mechanism in which these new therapies help to improve tumour cell death.

Findings

Protein analysis, confirmed that LY2606368 stopped the activation of the protein called cell cycle checkpoint kinase 1/2. We also determined

that this prevented glioblastoma cells from repairing damage caused by radiotherapy or chemotherapy such as temozolomide or gemcitabine, therefore, glioblastoma cells remain damaged and accumulated more damage. Through cell analysis we were able to determine that these damaged glioblastoma cells over time start to undergo the process of cell death.

Significance
These experiments help us understand how the LY2606368 is working to enhance glioblastoma cell death.

AIM 3

Examine whether combining new therapies to radiation therapy or chemotherapies such as temozolomide and gemcitabine will provide a survival benefit.

Current Findings
Using three different glioblastoma cell lines, we implanted these cells into the brains of mice. The combination treatment of LY2606368 with radiotherapy, temozolomide or gemcitabine reduced tumour cell growth and increased tumour cell DNA damage. Using our mice models of glioblastoma we have also shown that combining LY2606368 to radiotherapy, temozolomide or gemcitabine significantly extend survival when compared to single therapy.

Significance
LY2606368 is also known as prexasertib and is currently in clinical trial for other solid tumours such as ovarian and breast cancers. The data collected from this project is helping to establish a proposal for a future clinical trial for glioblastoma patients.

■ **Tracey Seymour—PhD student from The University of Western Australian and Telethon Kids Institute**

> The Lions Cancer Institute Inc. continues to support PhD Students involved with all types of cancer research. We can only wish these dedicated young people every success and hope that our continued financial support will one day lead to a better understanding and possible cure?
>
> - LCI Chairman

CONFERENCE ATTENDANCE

1. Seymour T, Kuchibhotla M, Nowak A, Gottardo N & Endersby R. Improving conventional therapy for glioblastoma via cell cycle checkpoint inhibition. Lorne Cancer Conference, Victoria. February 2019. Flask Talk and Poster Presentation
2. Seymour T, Kuchibhotla M, Nowak A, Gottardo N & Endersby R. Exploring cell cycle checkpoint inhibition and gemcitabine treatment for glioblastoma, Trials Group for Neuro-Oncology Scientific Meeting, Brisbane, October 2018. Oral Presentation
3. Seymour T, Kuchibhotla M, Nowak A, Gottardo N & Endersby R. Exploring cell cycle checkpoint inhibition and gemcitabine treatment for glioblastoma, Combined Biological Sciences Meeting, Perth August 2018. Poster Presentation
4. Seymour T, Kuchibhotla M, Nowak A, Gottardo N & Endersby R. Exploring cell cycle checkpoint inhibition and gemcitabine treatment for glioblastoma, Australian Society for Medical Research, Perth June 2018. Oral Presentation
5. Seymour T, Kuchibhotla M, Nowak A, Gottardo N & Endersby R. Cell cycle checkpoint inhibition enhances conventional glioblastoma treatments. Lorne Cancer Conference, Victoria. February 2018. Poster Presentation

NATIONAL CATEGORY 'B' SKIN CANCER SCREENING PROJECT

REPORT TO MD CABINET JULY 2019

National Category 'B' Skin Cancer Screening Project

The National Project commenced in effect from July 1, 2018 following a submission by C1 & C2 Districts jointly with W1 & W2 to the Townsville M D Convention, being approved by a majority vote to become a Category 'B' Project for a term of three years to June 30, 2021.

Western Australia commenced its screening program in 1990 and has conducted skin cancer screenings continuously, operating as the Lions Cancer Institute Inc. It has screened in the order of 80,000 people in that time, all over the State.

South Australia commenced operation in 2012 and operates as a sub-committee under the Lions Medical Research Foundation of South Australia. The project in SA was set up with the assistance and guidance of the WA operation. It has screened around 13,000 people to date, including in the NT.

The Lions V Districts Cancer Foundation Inc commenced being established in September 2018 and is expected to become operational in early 2020, once again with the guidance of the WA project.

Each State project is independently Incorporated and has its own Charitable Institution status needed to cover donations and equipment purchases. Accordingly, it is not appropriate to report as one project, but as a group of independent projects as shown below.

In order to ensure National support for the current States involved and others, some of whom have already expressed an interest in the project, a management committee is being setup which will include representatives from the LCI (WA) Board, The LMRF (SA) Board and the V Districts Board.

WESTERN AUSTRALIA DISTRICTS 201 W1 & W2 PREPARED

by PDG Colin Beauchamp AM JP

The West Australian project is going from strength to strength with an increasing number of requests by both Lions clubs, other community organisations and businesses seeking skin screening services. The support of the Western Australian Chapter of Dermatology and several GP's combined with our fully trained Dermoscopists and Nurses has allowed the teams to increase the number of screening this year.

We now have a formal agreement in place with HealthCert Queensland, which is University based to provide a certificated course in Assessment and Diagnosis of skin cancer lesions. There are currently three Trainees involved studying the above course. This course will be available to all states involved in the project at a heavily discounted rate.

The table below shows the results from screening at 37 locations throughout Western Australia.

SUMMARY SCREENING RESULTS
July 2018 -June 2019 - W Districts

Total	2842
Met Criteria	1076
Referred	563
Life Threatening Lesions	456
% Referred	20%
Last Screened within 6 months	101
Last Screened 6 - 12 months	324
Last Screened over 12 months	1183
Never Screened	910
Hours Driving	184
Hours Screening	1171

One of the most important factors continually presenting at most screenings outside of the Perth metropolitan area is that out of the 2,842 persons screened 1,183 had not had a full body screening within the last 12 months and 910 had never been screened before. This puts the total number "at risk" at 2,093 i.e. 73.6%. As such, and in consideration of the 20% referral rate, it highlights the probable value and need for this community activity to occur. The Institute expects to conduct screenings at over 40 locations in 2019.

The Western Australian team will continue to travel to other states as required. One of our senior screeners has been travelling to South Australia and Victoria to support and assist with screening, training and set up of the projects.

SOUTH AUSTRALIA DISTRICTS C201 C1 & C2

by PDG Marilyn Millar OAM, Subcommittee Chairperson

The South Australian project and its screenings has been very well received through the South Australian and Northern Territory. We have come to increasingly understand its value and necessity to the community and members of the public.

We continue to build our infrastructure, screeners and volunteer base. We need to thank the Lions Clubs within the C1 and C2 Districts for their ongoing support and assistance to make this project a successful reality with

NATIONAL CATEGORY 'B' SKIN CANCER SCREENING PROJECT

a wonderful opportunity "to serve".

Funds are being raised for a replacement truck due to the distances being travelled. A second-hand truck was originally purchased to meet budget, however, maintenance in the near future would not be cost effective.

Advertising and promotion have been extremely good. Interviews with ABC regional radio stations and articles in regional papers promotes Lions in a very positive manner. Providing Lions Clubs with a free Community Health Service to promote their Club in their area has proven to be a positive Club Care project by the C Districts. It is expected to conduct screenings at 19 locations during 2019.

The project has screened on 32.5 days within the reporting period. The table below shows that of the 2,430 people screened, an alarming total of 2,123 had either never been screened before or had been screened over 12 months prior.

SUMMARY SCREENING RESULTS
July 2018 -June 2019 – C Districts

Total	2430
Met Criteria	
Referred	590
Life Threatening Lesions	636
% Referred	24%
Last Screened within 6 months	60
Last Screened 6 - 12 months	251
Last Screened over 12 months	752
Never Screened	1371
Hours Driving	448
Hours Screening	638

LIONS 'V' DISTRICTS CANCER FOUNDATION INC SUPPORTED BY "V" DISTRICTS OF VICTORIA AND SOUTHERN NEW SOUTH WALES

by PCC Bruce Hudgson, Chair Victorian Project

The most recently incorporated Lions Foundation, the Lions V Districts Cancer Foundation, is now operational and DGR (deductible gift recipient) status is on the way. The call is out for V District Lions Clubs to offer their support, by donating - helping us to make this most valuable project a reality. We need as much as $250,000 to make this project a reality and running costs will be as much as $90,000 per annum.
The concept is based on the successful Lions Skin Cancer Screening programs in Western Australia and South Australia.

The provision of a Skin Screening Unit for Victoria and Southern New South Wales is the Foundation's initial project and is viewed as the next step in achieving a National program, importantly filling an essential service gap in Victoria and Southern New South Wales. The need Australia has one of the highest skin cancer rates in the world. This is nothing to be proud of. With our love of the outdoors and our, at times, harsh climate, as a people we are often exposed to the dangers of excessive amounts of ultraviolet radiation. Despite many campaigns and promotions, people remain ambivalent to checking for possible lesions, and attitudes about sun protection and prevention remain mixed - with many people still not taking adequate measures to protect themselves.

People living in regional areas are more at risk, with mortality rates higher in those areas, which can be attributed to a higher proportion of outdoor workers, poor accessibility to dermatologists and inadequate approaches to sun protection.

Accessibility to skin checks and, in turn, to skin specialists is limited. GP's with suitable vision magnification tools can help, but this method is not as accurate as the use of a dermoscope by a trained practitioner, and still presumes that people are requesting a check of their skin.

A free skin screening service is needed to ensure greater accessibility to service and most importantly, a service that will save lives!

The requirements to make this project a reality, a truck, van, generator and suitable skin check equipment will be needed. Also needed are trained dermoscopists - so volunteers are sought and training programs will be offered

The part The part that local Lions Clubs will play is very important in ensuring the project is a success. Clubs, especially from rural and remote areas, will seek a booking for a van visit. An annual roster will be created as a result of booking requests. Clubs will then manage the skin check booking system, find a suitable location for the van and assist with the management of the visit.

- **Lion Phil Chinnery—Chairman Lions Cancer Institute Inc (WA)**
- **Lion Phillip R Donato OAM—Chairman Lions Medical Research Foundation (SA)**
- **PCC Bruce Hudgson—Chairman Victorian Project**

File: Cat B Project Report July 2019 final

TREASURER'S REPORT

PDG NEIL SAUNDERS

The Institute has had a successful year.

As per previous years, our operating costs exceeded our operating income, received from Clubs and other donations.

Our Fundraising activities have helped us refrain from having to use any of our investment income, which is allowing the Portfolio to grow towards a target where we hope to be financially independent.

PORTFOLIO

Our Portfolio is starting to show the growth we have been expecting.

Our net growth for the past financial year was $48,733.91. This is a calculated growth of 7.22%. Remembering this is a conservative portfolio, it is far better than the current 6 monthly term on offer from the Bank of Sydney of 2.33%.

As at the 30.06.2019 our balance stood at $878,919.78.

Our Asset Class distribution, as at June 30th consisted of:

Cash	29.10%
Australian fixed interest	13.40%
Global fixed interest	11.10%
Property	05.10%
Australian Shares	22.20%
Global Shares	19.10%

OPERATIONAL ACCOUNTS

As previously mentioned, our operating expenses exceeded our general income. This year it was by the sum of $106,170.00.

Again, as usual, our other income sources have put the Institute in a financial position where we show a net (unaudited) surplus of approximately $177,554.33.

Our other income sources include the Portfolio growth, and a net return from our Telemarketing of $164,098.32.

The introduction of Electronic Fund Transfer facilities that can be used in our mobile units has seen an increase in on-site donations during screening events.

BUDGET

Our 2018/2019 Budget, compared to Actuals, was $19,592.00 under budget.

While I am pleased with the result, I consider the following points to be of interest.

The main reason for this is our Screening Expenses came in $19,646.00 under expected costs. Well done John.

Our budget of $10,200.00 for Training was an overestimate, with actual cost only coming to $3,113.00 for the year. This was due to the arrangement with HealthCert where some courses were provided free of charge. Thanks to Rob and Colin.

Net income was 0.5% under Budget.

Administration expenses were $2,337.00 over Budget. This was mainly for the setup costs of the new web site, which were $2,420.00.

Vehicle expenses were $52,098.00 for the year, over budget by $2,898.00. Of the total, $35,035.00 was for maintenance issues.

Unfortunately, we did not budget for any costs related to trying to expand into New Zealand.

The Board approved a trip to New Zealand's Multiple District Convention and PDG Colin Beauchamp and PDG Garry Irvine attended. The overall costs were $5,012.00.

With our recent commitment to fund a Scholarship at Curtin University, as well as our ongoing commitment to the Karen and Joshua Chinnery Scholarship we will have to remain vigilant of our costs and continue to look for opportunities to increase our income.

Many thanks to Lion David Baird for his untiring efforts in keeping the data entries into our MYOB account up to date

■ **PDG Neil F Saunders—Treasurer**

FINANCIAL REPORT - DIRECTOR'S REPORT

Your Directors present their report on the Institute for the financial year ended 30 June 2019.
The names of the Directors in office at the date of this report are:

ELECTED MEMBERS

Lion Phil Chinnery	Chairman
PDG Pamela Baird	Vice Chairman
PDG Garry Irvine	Director PR/Business Development
Lion David Baird	Director Assistant Treasurer
Lion John Osborne	Director Screening Event Co-ordinator
Lion Mary Austin	Director
Lion Stephen Berry	Director
Lion Michael Wainwright	Director
Lion June Walker	Director

APPOINTED MEMBERS

William (Bill) Crosthwaite	Secretary
PDG Neil F. Saunders	Treasurer
Dr Rob Fitzpatrick, FRCS, FRACS	Chair Medical & Scientific Advisory Committee

EX OFFICIO MEMBERS

1st VDG Daniel Stevens	1st VDG District 201W1
1st VDG Frank Camarri	DG District 201W2
VDG Dot Jacobs	1st VDG District 201W2
Lion Leonie Getty JP	District Chairman 201W1

CO-OPTED, NON-VOTING, MEMBERS

PDG Colin C. Beauchamp AM JP	Western Australia

CHANGE IN DIRECTORS DURING THE 2018/2019 FINANCIAL YEAR

DG Sue Lowe	End of term.
DG Grant Hewitt	End of term.
VDG Luen Chicote	End of term.
VDG Bev Hawkins	End of term.
Lion Mary-Anne Wolfe	Resigned.
Lion Dale Thomson	Resigned

No significant changes in the Institute's state of affairs occurred during the financial year. The Lions Cancer Institute Inc. is a "Not for Profit" medical research institution. The Institute holds endorsements for the Australian Taxation Office as an Income Tax exempt Charitable Entity (ITEC) and is a Deductible Gift Recipient (DGR). The Institute is also registered with Australian Charities and Not for Profits Commission (ACNC)

The Institute holds a current West Australian Charitable Collections Licence under the provisions of the Charitable Collections Act 1946.

No significant change in the nature of these activities occurred during the year.

No matters or circumstances have arisen since the end of the financial year which significantly affected or may significantly affect the operations of the Institute, the results of those operations, or the state of affairs of the economic entity in future financial years.

Signed in accordance with a resolution of the Board of Directors:

William John Osborne
Director
Place: Mandurah
Dated: 16.08.2019

Neil F Saunders
Treasurer
Place: Mandurah
16.08.2019

FINANCIAL REPORT - INCOME STATEMENT

INCOME STATEMENT FOR THE YEAR ENDED 30 JUNE 2019

	Note	2019 (in $)	2018 (in $)
Donations		64,085.59	61,301.65
Show account income		824,622.64	816,415.73
SA Revenue		15,403.19	33,194.59
Portfolio distribution income		35,528.18	43,409.96
Change in net market value of investments		19,955.51	7,759.74
Other income		3,745.00	11,087.15
Administration expenses		(33,264.85)	(22,300.86)
Depreciation and amortisation expenses	2	(58,521.50)	(54,915.11)
Fundraising expenses		-	(20.91)
Portfolio expenses		(4,746.88)	(2,280.02)
Scholarship and award expenses		(24,028.54)	(6,000.00)
Screening expenses		(63,730.49)	(64,657.70) ,
Show account expenses	3	(648,329.29)	(660,822.58)
Skin cancer screening unit		(54,465.67)	(48,662.80)
South Australia costs		(37,430.66)	(28,304.54)
Staff expenses		(1,747.90)	(5,291.15)
Other expenses	4	(8,124.71)	(8,143.96)
SURPLUS FROM ORDINARY ACTIVITIES BEFORE INCOME TAX		**28,949.62**	**71,769.19**
Retained surplus at the beginning of the financial year		1,095,878 87	I ,066,929 25
TOTAL AVAILABLE FOR APPROPRIATION		**1,095,878.87**	**1,066,929.25**

BALANCE SHEET AS AT 30 JUNE 2019

	Note	2019 (in $)	2018 (in $)
CURRENT ASSETS			
Receivables	5	277.00	13,418.00
Cash assets	6	196,586.00	210,738.75
other assets	7	6,170.16	9,476.99
TOTAL CURRENT ASSETS		**203,033.16**	**233,633.74**
NON-CURRENT ASSETS			
Property, plant and equipment	8	96,262.24	151,982.06
Intangible assets	9	2,815.91	
Financial assets	10	878,919.78	770,185.87
TOTAL NON-CURRENT ASSETS		**977 997.93**	**922,167.93**
TOTAL ASSETS		**1,181,031.09**	**1,155,801.67**
CURRENT LIABILITIES			
Payables	11	92,521.56	89,047.68
Credit card liabilities		302.16	9.60
GST accrued		(7,671.50)	(184.86)
TOTAL CURRENT LIABILITIES		**85,152.22**	**88,872.42**
TOTAL LIABILITIES		**85,152.22**	**88,872.42**
NET ASSETS		**1,095,878.87**	**1,066,929.25**
EQUITY			
Accumulated surplus		1,095,878.87	1,066,929.25
TOTAL EQUITY		**1,095,878.87**	**1,066,929.25**

STATEMENT OF CHANGES IN EQUITY AS AT 30 JUNE 2019

	2019 (in $)	2018 (in $)
Total equity at the beginning of the financial year	**1,066,929.25**	**995,160.06**
Surplus attributable to members	28,949.62	71,769.19
Total equity at the end of the financial year	**1,095,878.87**	**1,066,929.25**

STATEMENT OF CASH FLOWS FOR THE YEAR ENDED 30 JUNE 2019

	Note	2019 (in $)	2018 (in $)
CASH FLOWS FROM OPERATING ACTIVITIES			
Receipts from customers		926,658.58	911,336.91
Payments to suppliers and employees		(875,656.24)	(853,203.03)
Dividends received		35,528.18	43,409.96
Interest received		1,199.36	479.69
GST refund		(7,486.64)	(593.95)
Net cash provided by operating activities	12	80,243.24	101,429.58
CASH FLOWS FROM INVESTING ACTIVITIES			
Purchase of property, plant and equipment		(5,617.59)	(9,260.00)
Purchase of investments		(88,778.40)	(104,061.94)
Net cash provided by investing activities		(94,395.99)	(113,321.94)
CASH FLOWS FROM FINANCING ACTIVITIES			
Net increase in cash held		(14,152.75)	(11,892.36)
Cash at the beginning of year		210,738.75	222,631.11
Cash at end of year		196,586.00	210,738.75

NOTE 1: STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES

(a) Basis of Preparation

This financial report is a special purpose financial report prepared in order to satisfy the requirements of Board members to prepare a financial report. The Board members have determined that the Association is not a reporting entity. The financial report has been prepared in accordance with the requirements of Association Incorporation Act 2015 (WA), association regulations.

The financial statements have been prepared on an accruals basis and are based on historic costs and do not take into account changing money values or, except where specifically stated, current valuations of non-current assets. The following material accounting policies, which are consistent with the previous period unless otherwise stated, have been adopted in the preparation of the financial statements.

(b) Cash and Cash Equivalents

Cash and cash equivalents include cash on hand, deposits held at call with banks, other short term highly liquid investments with original maturities of three months or less.

(c) Property, Plant and Equipment

Leasehold improvements and office equipment are carried at cost less, where applicable, any accumulated depreciation.

The depreciable amount of all PPE is depreciated over the useful lives of the assets to the association commencing from the time the asset is held ready for use.

Leasehold improvements are amortised over the shorter of either the unexpired period of the lease or the estimated useful lives of the improvements.

(d) Impairment of Assets

At the end of each reporting period, the committee reviews the carrying amounts of its tangible and intangible assets to determine whether there is any indication that those assets have been impaired. If such an indication exists, an impairment test is carried out on the asset by comparing the recoverable amount of the asset, being the higher of the asset's fair value less costs of disposal and value in use, to the asset 's carrying amount. Any excess of the asset's carrying amount over its recoverable amount is recognised in the income and expenditure statement.

(e) Accounts Receivable and Other Debtors

Accounts receivable and other debtors include amounts due from members as well as amounts receivable from donors. Receivables expected to be collected within 12 months of the end of the reporting period are classified as current assets. All other receivables are classified as non-current assets.

(f) Revenue and Other Income

Revenue is recognised when the amount of the revenue can be measured reliably, it is probable that economic benefits associated with the transaction will flow to the entity and specific criteria relating to the type of revenue as noted below, has been satisfied.

Revenue is measured at the fair value of the consideration received or receivable and is presented net of returns, discounts and rebates. For this purpose, deferred consideration is not discounted to present values when recognising revenue.

Interest revenue is recognised using the effective interest method, which for floating rate financial assets is the rate inherent in the instrument. Dividend revenue is recognised when the right to receive a dividend has been established.

Grant and donation income is recognised when the entity obtains control over the funds, which is generally at the time of receipt.

If conditions are attached to the grant that must be satisfied before the association is eligible to receive the contribution, recognition of the grant as revenue will be deferred until those conditions are satisfied.

Other revenue is recognised when the institute is entitled to the funds. All revenue is stated net of the amount of goods and services tax.

(g) Leases

Leases of PPE, where substantially all the risks and benefits incidental to the ownership of the asset (but not the legal ownership) are transferred to the association, are classified as finance leases.

Finance leases are capitalised by recording an asset and a liability at the lower of the amounts equal to the fair value of the leased property or the present value of the minimum lease payments, including any guaranteed residual values. Lease payments are allocated between the reduction of the lease liability and the lease interest expense for that period.

Leased assets are depreciated on a straight-line basis over the shorter of their estimated useful lives or the lease term. Lease payments for operating leases, where substantially all the risks and benefits remain with the lessor, are charged as expenses in the periods in which they are incurred.

(h) Goods and Services Tax (GST)

Revenues, expenses and assets are recognised net of the amount of GST, except where the amount of GST incurred is not recoverable from the Australian Taxation Office (ATO).

In these circumstances, the GST is recognised as part of the cost of acquisition of the asset or as part of an item of the expense.

Receivables and payables are stated inclusive of the amount of GST receivable or payable. The net amount of GST recoverable from, or payable to, the ATO is included with other receivables or payables in the statement of financial position.

(i) Financial Assets
Investments in financial assets are initially recognised at cost, which includes transaction costs, and are subsequently measured at fair value, which is equivalent to their market bid price at the end of the reporting period. Movements in fair value are recognised through an equity reserve.

j) Accounts Payable and Other Payables
Accounts payable and other payables represent the liability outstanding at the end of the reporting period for goods and services received by the association during the reporting period that remain unpaid. The balance is recognised as a current liability with the amounts normally paid within 30 days of recognition of the liability.

(k) Provisions
Provisions are recognised when the association has a legal or constructive obligation, as a result of past events, for which it is probable that an outflow of economic benefits will result and that outflow can be reliably measured. Provisions are measured at the best estimate of the amounts required to settle the obligation at the end of the reporting period.

(l) Income Tax
Lions Cancer Institute Inc. is exempt from income tax and registered as deductible gift recipient.

NOTE 2: DEPRECIATION AND AMORTISATION EXPENSES

	2019 (in $)	2018 (in $)
Amortisation	704.00	-
Depreciation - plant and equipment	57,817.50	54,915.11
	58,521.50	54,915.11

NOTE 3: SHOW ACCOUNT EXPENSES

	2019 (in $)	2018 (in $)
Show account expenses	647,235.18	659,924.89
Show account bank fee	1,094.11	897.69
	648,329.29	660,822.58

NOTE 4: OTHER EXPENSES

	2019 (in $)	2018 (in $)
New Zealand set up	5,011.79	-
ANZI2017	-	386.65
Training	3,112.92	5,180.36
Corporate Expenses	-	2,576.95
	8,124.71	8,143.96

NOTE 5: RECEIVABLES

	2019 (in $)	2018 (in $)
Fuel tax receivable	277.00	-
Trade debtors	-	13,418.00
	277.00	13,418.00

NOTE 6: CASH ASSETS

	2019 (in $)	2018 (in $)
Westpac #3738	14,215.86	12,536.34
Cash Reserve Bonus 635-033	69,739.40	100.00
Business cash reserve 8557	51.85	97,148.37
SA/NT #620-173	40.19	8,095.39
Community solution account 0011	112,538.70	92,858.65
Term deposit - short term	-	-
Interest accrued	-	-
	196,586.00	210,738.75

NOTE 7: OTHER ASSETS

	2019 (in $)	2018 (in $)
Prepayments	-	6,860.52
Credit Card- - W John Osborne	6,170.16	1,396.95
Credit Card - C Beauchamp	-	1,219.52
	6,170.16	9,476.99

NOTE 8: PROPERTY, PLANT AND EQUIPMENT

	2019 (in $)	2018 (in $)
UHF Radio	452.73	452.73
Less accumulated depreciation	(452.73)	(452.73)
Photo Finder	24,110.00	24,110.00
Less accumulated depreciation	(24,110.00)	(24,110.00)
Generator	14,200.00	14,200.00
Less accumulated depreciation	(13,189.90)	(11,160.72)
Dermalite 11 multispectral	7,976.82	6,681.82
Less accumulated depreciation	(6,712.57)	(6,681.82)
Screening equipment	12,558.14	12,558.14
Less accumulated depreciation	(6,518.98)	(2,784.44)
Coach IEFV 432	305,754.62	305,754.62
Less accumulated depreciation	(231,694.07)	(193,474.74)
Molecam	1,813.64	1,813.64
Less accumulated depreciation	(1,813.64)	(1,813.64)
Van 1TNK 399	83,965.46	83,965.46
Less accumulated depreciation	(70,408.40)	(59,912.72)
Notebook computer	559.09	559.09
Less accumulated depreciation	(559.09)	(559.09)
iPhone 4	390.00	390.00
Less accumulated depreciation	(390.00)	(390.00)
Coach 1EFV432 -Sat. phone	4,698.00	4,698.00
Less accumulated depreciation	(4,698.00)	(3,311.37)
Van 1TNK 399 -Sat. phone	2,220.45	2,220.45
Less accumulated depreciation	(2,220.45)	(1,559.02)
Tvs - Van and Coach	580.87	580.87
Less accumulated depreciation	(580.87)	(470.78)
Lumino Screening Lamps	1,041.67	1,041.67
Less Accumulated Depreciation	(710.55)	(363.36)
Olympus camera electronic	802.68	-
Less accumulated depreciation	(802.68)	-
	96,262.24	151,982.06

NOTE 9: INTANGIBLE ASSETS

	2019 (in $)	2018 (in $)
Website	3,519.91	-
Less amortisation	(704.00)	-
	2,815.91	-

NOTE 10: FINANCIAL ASSETS

	2019 (in $)	2018 (in $)
Colonial First State	851,204.53	762,426.13
Change in market value	27,715.25	7,759.74
	878,919.78	770,185.87

NOTE 11: PAYABLES

	2019 (in $)	2018 (in $)
Trade creditors	92,521.56	89,047.68

NOTE 12: CASH FLOW INFORMATION

For the purposes of the statement of cash flows, cash includes cash on hand and in at call deposits with banks or financial institutions, investments in money market instruments maturing within less than two months, net of bank overdrafts.

a. Reconciliation of Cash

Cash at the end of the reporting period as shown in the statement of cash flows is reconciled to the related items in the statement of financial position as follows:

	2019 (in $)	2018 (in $)
Cash on hand	196,586.00	210,738.75

b. Reconciliation of Cash Flow from Operations with Profit from Ordinary Activities after Income Tax

	2019 (in $)	2018 (in $)
Surplus after income tax	28,949.62	71,769.19
Amortisation	704.00	-
Depreciation	57,817.50	54,915.11
Change in market value of investments	(19,955.51)	(7,759.74)
(Increase) / Decrease in trade and other receivables	20,001.52	(10,182.52)
Increase / (Decrease) in trade and other payables	212.75	(6,718.51)
Increase / (Decrease) in taxes payable	(7,486.64)	(593.95)
Cash flow from operations	80,243.24	101,429.58

FINANCIAL REPORT - DIRECTORS' DECLARATION

Lions Cancer Institute Inc.

ABN 26 521 960 054

DIRECTORS' DECLARATION

The Board of Directors have determined that the Association is not a reporting entity and that this special purpose financial report should be prepared in accordance with the accounting policies outlined in Note 1 to the financial statements, the attached special purpose financial statements have been prepared for the purpose of complying with the Association Incorporation Act 2015 (WA), the Australian Charites and Not-for-Profits Commission Act 2012 and association regulations;

The directors of the Association declare that:

1. the financial statements and notes attached give a true and fair view of the financial position as at 30/06/2019 and its performance for the year ended on that date in accordance with the accounting policies described in Note 1 to the financial statements;

2. in the directors' opinion there are reasonable grounds to believe that the incorporated association will be able to pay its debts as and when they become due and payable.

This statement is made in accordance with a resolution of the Board of Directors and is signed for and on behalf of the directors by.

Chairman:

Treasurer:

Dated : 15 October 2019

INDEPENDENT AUDITOR'S REPORT

Lions Cancer Institute Inc.

ABN 26 521 960 054

INDEPENDENT AUDITOR'S REPORT
TO THE MEMBERS OF
Lions Cancer Institute Inc.

Report on the Audit of the Financial Report

Opinion
We have audited the financial report of Lions Cancer Institute Inc. (the association), which comprises the assets and liabilities statement as at 30/06/2019, the income and expenditure statement for the year then ended, notes comprising a summary of significant accounting policies and other explanatory information, and the certification by members of the board of directors on the annual statements giving a true and fair view of the financial position and performance of the association.
In our opinion, the accompanying financial report gives a true and fair view of the financial position of Lions Cancer Institute Inc. as at 30/06/2019 and of its financial performance for the year then ended in accordance with the accounting policies described in Note 1 to the financial statements, and the requirements of The Associations Incorporation Act 2015 (WA).

Basis for Opinion
We conducted our audit in accordance with Australian Auditing Standards. Our responsibilities under those standards are further described in the *Auditor's Responsibilities for the Audit of the Financial Report* section of our report. We are independent of the association in accordance with ethical requirements of the Accounting Professional and Ethical Standards Board 's APES 110: *Code of Ethics for Professional Accountants* (the Code) that are relevant to our audit of the financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.
We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Emphasis of Matter - Basis of Accounting
We draw attention to Note 1 to the financial report, which describes the basis of accounting. The financial report has been prepared to assist the association to meet the requirements of The Associations Incorporation Act 2015 (WA) . As a result, the financial report may not be suitable for another purpose. Our opinion is not modified in respect of this matter.

Responsibilities of the Board of Directors for the Financial Report
The board of directors is responsible for the preparation and fair presentation of the financial report in accordance with the financial reporting requirements of The Associations Incorporation Act 2015 (WA) and for such internal control as the board of directors determines is necessary to enable the preparation and fair presentation of a financial report that is free from material misstatement, whether due to fraud or error.
In preparing the financial report, the board of director is responsible for assessing the association' s ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the board of directors either intends to liquidate the association or to cease operations, or have no realistic alternative but to do so The board of directors is responsible for overseeing the association 's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Report
Our objectives are to obtain reasonable assurance about whether the financial report as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor 's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the Australian Auditing Standards will always detect a material misstatement when it exists.

INDEPENDENT AUDITOR'S REPORT

Lions Cancer Institute Inc.
ABN 26 521 960 054

Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this financial report.

- As part of an audit in accordance with the Australian Auditing Standards, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial report, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the association 's internal control.

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the board of directors.

- Conclude on the appropriateness of the board of directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the association 's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor 's report to the related disclosures in the financial report or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor 's report. However, future events or conditions may cause the association to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the financial report, including the disclosures, and whether the financial report represents the underlying transactions and events in a manner that achieves fair presentation.

We communicate with the board of directors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Auditax Accountants
Chartered Accountant

Dharam Ghangas
Director

Place: Perth
Dated: 15/10/2019

Lions Cancer Institute Inc.

ABN 26 521 960 054

INCOME AND EXPENDITURE STATEMENT

For the year ended 30 June 2019

	2019 $	2018 $
INCOME		
Donations - Lions Clubs	43,600.00	42,095.00
Donations- screening unit	6,524.70	9,882.10
Donations- private	3,079.54	2,870.75
Jesse Martin cash tin	3,841.35	200.00
Donations- corporate	5,040.00	3,253.80
Karen & Joshua Chinnery scholarship	2,000.00	3,000.00
SA Telemarketing	15,403.19	32,994.59
South Australia Set Up	-	200.00
Corporate screening	1,613.64	8,545.46
Distribution - Colonial First State	33,194.18	41,341.96
Franking Credits Refund	2,334.00	2,068.00
Fuel tax credits	932.00	952.00
Show account income	824,622.64	816,415.73
Sun Smudge income	-	1,110.00
Westpac bank interest	1,199.36	479.69
	943,384.60	965,409.08
EXPENDITURE		
ANZI 2017	-	386.65
Office rental	1,214.90	1,130.18
Insurance	4,602.48	4,183.85
Presentation	13.64	235.45
Postage and shipping	670.84	321.91
Bank charges	227.73	325.46
Computer supplies	2,241.31	1,139.19
Telephone expenses	2,703.38	1,820.12
Accounting and audit	4,289.11	3,581.78
New Zealand set up	5,011.79	-
Stationary and printing	6,193.12	3,863.70
Bad debts	1,264.25	-
Corporate Expenses	-	2,576.95
Vehicle Storage	3,885.94	3,856.51
Screening forms	1,916.63	-
Public relations	4,041.52	1,842.71
Staff amenities	156.13	497.91
Sundry exp	322.60	397.92
Other employer expenses	1,269.17	4,395.32
Fundraising expenses	-	20.91
Screening expenses	2,241.07	589.44
Screening equipment repairs	1,176.89	177.27

These statements should be read in conjunction with the attached compilation report.

AUDITOR'S REPRESENTATION LETTER 1/3

Lions Cancer Institute Inc.
PO Box 2195, MANDURAH DC WA 6210

15 October 2019

Auditax Accountants
PO Box 8337 Perth BC WA 6849

Dear Sir

Lions Cancer Institute Inc.

This representation letter is provided in connection with your audit of the financial report of Lions Cancer Institute Inc.. for the year ended 30 June 2019. for the purpose of your expressing an opinion as to whether the financial report is, in all material respects, presented fairly in accordance with Australian Accounting Standards as presented in the financial report (including the Australian Accounting Interpretations), Association Incorporation Act 2015 (WA) and the Australian Charites and Not-for-Profits Commission Act 2012 and association regulation.

We acknowledge our responsibility for ensuring that the financial report is in accordance with Australian Accounting Standards as presented in the financial report (including Australian Accounting Interpretations) and Association Incorporation Act 2015 (WA). and confirm that the financial report is free of material misstatements, including omissions.

We confirm, to the best of our knowledge and belief, the following representations made to you during your audit.

1. We have provided you with:
   (a) access to all information, of which we are aware, that is relevant to the preparation of the financial report. Such as, records, documentation and other matters;
   (b) additional information that you have requested from us for the purpose of the audit; and
   (c) unrestricted access to persons within the entity from whom you determined it necessary to obtain audit evidence.
2. All transactions have been recorded in the accounting records and are reflected in the financial report.
3. We have disclosed to you:
   (a) the results of our assessment of the risk that the financial report may be materially misstated as a result of fraud.

(b) all information in relation to fraud or suspected fraud that we are aware of and that effects the entity and involves:
- management;
- employees who have significant roles in internal control; or
- others where the fraud could have a material effect on the financial report.

(c) all information in relation to allegations of fraud, or suspected fraud, affecting the entity's financial report communicated by employees, former employees, analysts, regulators or others.

(d) all known instances of non-compliance or suspected non-compliance with laws and regulations whose effects should be considered when preparing the financial report.

(e) the identity of the entity's related parties and al the related party relationships and transactions of which we are aware.

4. We have provided you with all requested information explanations and assistance for the purposes of the audit.

5. We acknowledge our responsibility for the design and implementation of internal control to prevent and detect error. We have established and maintained adequate internal control to facilitate the preparation of a reliable financial report, and adequate financial records have been maintained. There are no material transactions that have not been properly recorded in the accounting records underlying the financial report.

6. We have no plans or intentions that may materially affect the carrying values, or classification, of assets and liabilities.

7. We have considered the requirements of AASB 136, "Impairment of Assets", when assessing the impairment of assets and in ensuring that no assets are stated in excess of their recoverable amount.

8. The following have been properly recorded and/or disclosed in the financial report:

(a) related party transactions and related amounts receivable or payable, including sales, purchases, loans, transfers, leasing arrangements and guarantees (written or oral);

(b) share options, warrants, conversions or other requirements;

(c) arrangements involving restrictions on cash balances, compensating balances and line-of-credit or similar arrangements;

(d) agreements to repurchase assets previously sold;

(e) material liabilities or contingent liabilities or assets including those arising under derivative financial instruments;

(f) unasserted claims or assessments that our lawyer has advised us are probable of assertion; and

(g) losses arising from the fulfilment of, or an inability to fulfil, any sale commitments or as a result of purchase commitments for inventory quantities in excess of normal requirements or at prices in excess of prevailing market prices.

9. There are no violations or possible violations of laws or regulations whose effects should be considered for disclosure in the financial report or as a basis for recording an expense.

10. The entity has satisfactory title to all assets, and there are no liens or encumbrances on such assets nor has any asset been pledged as collateral. Allowance for depreciation has been adjusted for all important items of property, plant and equipment that have been abandoned or are otherwise unusable. We confirm that all assets listed in the deprecation schedule exist and owned by Lions Cancer Institute Inc. as of 30 June 2019.

11. The entity has complied with all aspects of contractual agreements that would have a material effect on the financial report in the event of non-compliance.

AUDITOR'S REPRESENTATION LETTER 3/3

12. The entity has complied with requirement of all funding agreements, grants terms and conditions. All expenses incurred were in accordance with objectives of Lions Cancer Institute Inc. and funding agreements.
13. There were no material commitments for construction or acquisition of property, plant and equipment or to acquire other non-current assets, such as investments or intangibles, other than those disclosed in the financial report.
14. We have no plans to abandon lines of product or other plans or intentions that will result in any excess or obsolete inventory, and no inventory is stated at an amount in excess of net realisable value.
15. All events subsequent to the date of the financial report and for which Australian Accounting Standards require adjustment or disclosure have been adjusted or disclosed in the financial report.

Environmental Matters

15. There are no violations or possible violation of laws or regulations where effects should be considered for disclosure in the financial report or as a basis for recording an expense.

Audit Adjustments

16. We confirm that the list of uncorrected misstatements that have been noted during your audit, has been brought to management's attention and that management has considered the effect of any such uncorrected misstatements, aggregated during and pertaining to the latest audit period, on the financial report and considers the misstatements are immaterial individually and in aggregate to the financial report taken as a whole.

We understand that your examination was made in accordance with Australian Auditing Standards and was, therefore, designed primarily for the purpose of expressing an opinion on the financial report of the entity taken as a whole, and that your tests of the financial records and other audit procedures were limited to those which you considered necessary for that purpose.

Yours faithfully

For and on behalf of the Board
Lions Cancer Institute Inc.

President

~~Secretary~~/Treasurer

CLUB DONATIONS 2018/2019

DATE	CLUB	RECEIPT #
16/07/2018	Atwell L.C.	5426
16/07/2018	Serpentine-Jarrahdale L.C.	5427
01/08/2018	Mandurah L.C.	5428
23/08/2018	Bridgetown L.C.	1274
23/08/2018	Stirling Inc. L.C.	1273
23/08/2018	Ballajura L.C.	1269
23/08/2018	Bull Creek L.C.	1270
23/08/2018	Hannans Goldfields L.C.	1271
02/10/2018	Pinjarra L.C.	5835
28/11/2018	East Fremantle L.C.	1276
28/11/2018	Tambellup L.C.	1277
06/12/2018	Claremont/Nedlands L.C.	5836
18/01/2019	Bencubbin L.C.	6568
18/01/2019	Jerramungup L.C.	6569
07/02/2019	Busselton L.C.	6275
20/02/2019	Manjimup L.C.	6497
20/02/2019	Kwinana L.C.	6567
28/02/2019	Dardanup L.C.	6565
28/02/2019	Bunbury Wollaston L.C.	6566
22/03/2019	Ellenbrook Lions L.C	6544
05/04/2019	Goomalling L.C.	1293
05/04/2019	Girrawheen L.C.	1294
05/04/2019	Donnybrook L.C.	1295
05/04/2019	Dongara/Denison L.C.	1296

DATE	CLUB	RECEIPT #
05/04/2019	Morley L.C.	1297
06/05/2019	Dunsborough L.C.	1298
15/05/2019	Collie L.C.	2356
15/05/2019	Forrestfield/High Wycombe L.C.	2357
28/05/2019	Bassendean L.C.	2502
06/06/2019	Armadale/Kelmscott L.C.	2503
14/06/2019	Duncraig L.C.	6923
17/06/2019	North Beach L.C.	6925
24/06/2019	Gingin/Chittering L.C.	6926
24/06/2019	East Fremantle L.C.	6927
27/06/2019	Albany South Coast L.C.	6930
27/06/2019	Booragoon L.C.	2365
27/06/2019	Bull Creek L.C.	2373
27/06/2019	Brunswick Junction L.C.	2359
27/06/2019	Capel L.C.	2367
27/06/2019	Cowaramup L.C.	2368
27/06/2019	Hannans Goldfields L.C.	2362
27/06/2019	Lake Grace L.C.	2371
27/06/2019	Narrogin L.C.	2366
27/06/2019	Rockingham L.C.	2369
27/06/2019	Three Springs L.C.	2372
27/06/2019	Whitford L.C.	2364
18/07/2019	Wagin L.C.	2379

Total Donated by Lions Clubs
$43,600.00

LIFE FELLOWS OF THE LIONS CANCER INSTITUTE INC.

PDG Garry Irvine	DIRECTOR
Mr Alister Turner MBBS FRCS FRACS	PLASTIC SURGEON
Mr Robert Fitzpatrick MBBS FRCS FRACS	PLASTIC SURGEON
Mr Barrie Lykke MBBS FRACS FRACS (Retired)	PLASTIC SURGEON
Professor Kurt Gebauer MBBS FACD	PROFESSOR OF DERMATOLOGY
Dr Lester Cowell MBBS	PRIMARY CARE SKIN CANCER PRACTIONER
Mrs Monika Cowell	DERMOGRAPHER
Lion Susan Goddard BA APP. Sc. FRCNA (Retired)	REGISTERED NURSE
PDG Colin Beauchamp AM.JP	DERMOGRAPHER
PDG RON VAUGHAN (Deceased)	
Mr DON PHILLIPS (Deceased)	

▲ CBC CENTENARY GRANT, SUCCESS WA

ego SUN SENSE™

30 years of Australian research and development ensures that SunSense sunscreens are for real Australian conditions and real Australian lifestyles. Developed to suit individual needs, SunSense sunscreens not only provide SPF protection, but offer the added benefits of moisturising Vitamin B3. The SunSense range is specifically formulated using high quality ingredients to provide specialised choices for all ages and skin types including sensitive skin and the delicate skin of young children.

Visit www.sunsense.com.au for more information.

All SunSense sunscreens are Australian made in Braeside, Victoria and Australian family owned.

Kwik Kopy DESIGN PRINT// SIGNAGE PROMO | 121 CREATIVE// MARKETING STRATEGY WEB+SOCIAL

Kwik Kopy Canning Vale has been established in the heart of Canning Vale since 1998. Fitz Cass has owned the company since 2007 and he is driven by a passion for the business and it's customers. Our success is due to constantly evolving together with our customers.

At Kwik Kopy Canning Vale, we keep things as simple as possible. We deliver great customer service from experienced staff and in-house production for fast, reliable service and high quality products. We can print just about everything you need.

Our goal is to offer you a wide range of products, from branding to print, signage, promotional products, merchandise, marketing, creative and digital services.

The team at Kwik Kopy Canning Vale
Fitz, Janelle and Céline

SAVING *lives* IN YOUR COMMUNITY THROUGH *screening* AND RESEARCH.

Lions Cancer Institute Inc.
PO Box 2195,
MANDURAH DC, WA 6210

Chairman
Mobile: 0428 420 275
Email: phil.chinnery@lionscancerinstitute.org.au

Treasurer
Mobile: 0418 947 345
Email: treasurer@lionscancerinstitute.org.au

www.lionscancerinstitute.org.au